Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Fostamatinib in Relapsed or Refractory DLBCL
2011-005371-16Phase 2Completed
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fostamatinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Rigel Pharmaceuticals, Inc.. Started Nov 2011; status: completed.
02
Drugs
fostamatinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2011-005371-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005371-16.